Minimal residual disease (MRD) detection is a critical role in the management of lymphoma. Traditionally, MRD assessment relies invasive bone marrow biopsies, which can be involve risks and discomfort for patients. Liquid biopsy, a minimally invasive approach, has emerged as a promising alternative for MRD detection in lymphoma. This method involve